Cargando…
Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
INTRODUCTION: Primary focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. There are no US Food and Drug Administration−approved therapies for FSGS, and treatment often fails to reduce proteinuria. Endothelin is an important factor in the pa...
Autores principales: | Komers, Radko, Gipson, Debbie S., Nelson, Peter, Adler, Sharon, Srivastava, Tarak, Derebail, Vimal K., Meyers, Kevin E., Pergola, Pablo, MacNally, Meghan E., Hunt, Jennifer L., Shih, Alvin, Trachtman, Howard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678638/ https://www.ncbi.nlm.nih.gov/pubmed/29142983 http://dx.doi.org/10.1016/j.ekir.2017.02.019 |
Ejemplares similares
-
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
por: Trachtman, Howard, et al.
Publicado: (2023) -
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
por: Komers, Radko, et al.
Publicado: (2020) -
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis
por: Wada, Russell, et al.
Publicado: (2023) -
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
por: Barratt, Jonathan, et al.
Publicado: (2023) -
Sparsentan: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)